Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Atai Beckley Inc.NASDAQ: ATAI

Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026

Other income / expenses turns positive

Q2 FY2026 other income / expenses was $11.66M, compared with -$2.41M a year earlier. Trailing-twelve-month other income / expenses was -$521.72M.

Context

  • Other income / expenses amounted to 13697.4% of revenue in FY2025, down 1964.6 pp from a year earlier.
  • Other income / expenses increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near $11.66M or moves back toward the trailing-twelve-month quarterly average of -$130.43M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$11.66M+941.7% QoQ
Last fiscal yearDec 2025
-$560.09M-1061.1% YoY
LTMJun 2026
-$521.72M-2303.3% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+584.1%——
1 year-1061.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
(560.09M) USD
Year-over-year change
-1061.1%

Other Income / Expenses vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -2303.3% is the lowest of 11, against a peer median of -19.6%.
  • Other income / expenses amounts to 11663.8% of revenue for ATAI, versus a peer median of 141.2%.
ATAI Competitors
Other Income / Expenses for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$187.94M USD+1139.2%+133.2%9870.5%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$24.4M USD-22.6%+44.2%235.7%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$21.88M USD+45.3%+141.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$14.69M USD+6.7%+72.3%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$12.59M USD+69.5%+32.0%—
IMTXImmatics N.V.LTM Mar 2026-€2.64M EUR-106.2%—7.1%
SANASana Biotechnology, Inc.LTM Mar 2026-$4.43M USD-212.0%——
INBXInhibrx Biosciences, Inc.LTM Mar 2026-$7.13M USD-100.4%—548.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$19.72M USD-255.1%—9.1%
NKTRNektar TherapeuticsLTM Jun 2026-$25.52M USD-16.6%—46.8%
ATAIAtai Beckley Inc.LTM Jun 2026-$521.72M USD-2303.3%—11663.8%
Peer median (excluding ATAI) —-19.6%+72.3%141.2%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.38M233K314K308K4.09M
Cost of Revenue47K168K319K473K1.01M
Gross Profit20.33M65K(5K)(165K)3.08M
Gross Margin99.8%27.9%-1.6%-53.6%75.3%
Research & Development47.91M74.15M61.88M54.98M53.06M
Selling, General & Admin92.75M70.35M63.58M47.54M49.78M
Operating Expenses140.65M144.5M125.47M102.53M102.84M
Depreciation & Amortization47K168K319K473K1.01M
EBITDA(178.19M)(150.1M)(39.9M)(147.33M)(657.68M)
EBITDA Margin-874.5%-64419.3%-12708.3%-47835.4%-16084.0%
Operating Income(120.33M)(144.43M)(125.47M)(102.69M)(99.76M)
Operating Margin-590.5%-61987.1%-39958.9%-33341.2%-2439.7%
Interest Income205K548K1.85M778K1.48M
Interest Expense0923K2.66M3.12M1.16M
Other Income / Expenses(57.91M)(6.76M)82.59M(48.24M)(560.09M)
Income Before Tax(178.23M)(151.19M)(42.88M)(150.93M)(659.85M)
Pre-Tax Margin-874.7%-64887.6%-13655.7%-49003.2%-16137.2%
Income Tax Expense(3.99M)6.23M1.02M(881K)298K
Net Income(167.81M)(152.39M)(40.22M)(149.27M)(660.05M)
Net Margin-823.6%-65401.3%-12810.2%-48464.0%-16142.0%
EPS (Basic)(1.04)(0.98)(0.25)(0.93)(2.91)
EPS (Diluted)(1.04)(0.98)(0.25)(0.93)(2.91)
Weighted Avg Shares160.68M155.72M158.83M160.16M226.53M
Weighted Avg Shares (Diluted)160.68M155.72M158.83M160.16M226.53M

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.